MEDIVIR AB – INTERIM REPORT, JANUARY – SEPTEMBER 2017
Positive data reported across multiple clinical programsJuly - September Significant events during the quarter · Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an acceptable safety and tolerability in this patient population. · FDA accepted Medivir´s IND application for MIV-711, enabling clinical development in the US. · The exclusive rights to MIV-802 for Greater China were outlicensed to Ascletis. · Clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid